Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00263042 · ClinicalTrials.gov registry record · Phase 3
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 18,695
- Enrollment target
NCT00263042 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 18,695 participants.
The verdict
NCT00263042, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 18,695 participants
- Enrollment target
Study Summary
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV hospitalization in these patients.
Interventions
- DRUG Rimonabant
- DRUG Placebo (for Rimonabant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,695 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00263042
The ClinicalTrials.gov registry entry for NCT00263042 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 18,695 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rimonabant is the first listed.
NCT00263042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00263042 about?
NCT00263042 is a clinical study titled "Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes". The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV...
What is the current status of trial NCT00263042?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 18,695 participants. The study started on 2005-12. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00263042?
The interventions under investigation include: Rimonabant (DRUG), Placebo (for Rimonabant) (DRUG).
Who is sponsoring clinical trial NCT00263042?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.